... and Memory. Marijuana is known to be an appetite stimulant, and a new class of anti-obesity drugs—such as rimonabant (trade name Acomplia) developed by Sanofi-Aventis and awaiting approval for use in ...
... increase cellular metabolism, and existing anti-obesity drugs may represent a new way to block ... viral therapeutic targets. Researchers combined drug discovery technologies to capture for the first time ...
... gap exists between the effectiveness of currently marketed obesity drugs and gastric-bypass surgery. Tesofensine ... twice the weight loss as currently approved drugs; however, larger phase III studies ...
EMEA has recommended that doctors stop prescribing Sanofi-aventis’ anti-obesity drug rimonabant
Designers of anti-obesity drugs have suffered three major setbacks, but the potential reward from treating the world's fat epidemic is so great that their quest is unlikely to be deterred.
... brain in order to develop safer anti-obesity drugs with fewer side effects. In a study ... serotonin 2c receptors expectedly developed obesity as well as other metabolism disorders such as increased food ...
Once hailed as a miracle weight-loss drug, Fen-phen was removed from the market more than a decade ago ... -phen behaves in the brain in order to develop safer anti-obesity drugs with fewer side effects.
Producing results it said would be good enough for regulatory approval, Arena Pharmaceuticals said its experimental obesity drug had succeeded in its first late-stage clinical trial.
... ) were widely prescribed as half of a so-called 'fen/phen' drug combination used to combat obesity. Since its withdrawal, there have been reports that tens of thousands of lawsuits have been filed ...
... at a special symposium on Obesity at the BPS Winter Meeting, which also includes a presentation on the regulatory challenges for new anti-obesity drugs. For the full programme please see below.
... leptin, an appetite-suppressing hormone, generated great hopes for an effective obesity drug. But hopes dimmed when it was found that obese people are leptin-resistant. Now, researchers have, for the ...
... companies eager to develop new anti-obesity drugs aimed at a novel, new molecular ... t know whether this gene is defective in some of the obese or metabolic syndrome patients – those are things that need ...
... from the intestine and secretion of VLDL and LDL from the liver. Although L-81 is a potent anti-obesity drug, its potential in alleviating obesity-induced insulin resistance and type 2 ...
Thousands of children and adolescents are using anti-obesity drugs that in the UK are only licensed for use by adults. The number of young people receiving prescriptions for these drugs has increased ...
Three small California companies are hoping to begin selling obesity drugs that could help treat one of the America’s biggest and costliest health problems.
